Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Mayne Pharma Group Ltd

MYX.AX ✓ COMPLIANT ☆ Track — members

ASX · Healthcare · Pharmaceuticals ·

Australia Micro Cap Analyst: BUY

Last Close

$2.27

▼ -1.23%

Market Cap $183.39M · Vol 254.14K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$183.39M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

-10,435.13%

YoY

RSI (14)

82.76

Momentum

Beta

0.80

vs Market

52W High

$4.60

46.24% below

52W Low

$1.44

58.16% above

Volume

254.14K

Avg 249.15K

P/B

1.10

Price-to-book

ROE

N/A

Return on equity

Free Float

86.85%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Mayne Pharma Group Ltd (MYX.AX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MYX.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.59%

+14.29%

+40.35%

+22.14%

YTD

+2.89%

-36.38%

-26.86%

-35.00%

Financials & Valuation

TTM · Annual

Total Revenue	$271.76M
Net Income	$-59,266,595.00
Revenue Growth (YoY)	-1.00%
Gross Margin	46.67%
Operating Margin	-4.21%
Net Profit Margin	-21.81%
ROE	N/A
ROA · ROIC	-7.72% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	0.96
P/B	1.10
P/FCF	N/A
EPS Growth	-10,435.13%
Outstanding Shares	81.25M

Technical Indicators

50-Day SMA	$1.94
200-Day SMA	$2.05
RSI (14)	82.76
Beta	0.80
52-Week High	$4.60
52-Week Low	$1.44

Volume Today	254.14K
Avg Daily Volume (30D)	249.15K
Relative Volume	1.02x
Volatility (10D)	49.49
Volatility (30D)	39.47
Free Float	86.85%

Analyst Consensus

BUY

Current Price $2.27

Mean Target $2.65

52W Low$1.44 52W High$4.60

Current

Target

$1.44 $4.60

Current Analyst target

+16.98% upside potential · 1 analysts

Identifiers

ExchangeASX

FIGIBBG001SDB363

ISINAU000000MYX0

CountryAustralia

Sub-IndustryGeneric Pharmaceuticals

Earnings DateAug 26, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

SUNPHARMA.NS Sun Pharmaceutical Industries Ltd -0.10% 4578.T Otsuka Holdings Co Ltd -3.26% CIPLA.NS Cipla Ltd -0.60% ZYDUSLIFE.NS Zydus Lifesciences Ltd -2.75% RICHTER.BU Richter Gedeon Vegyeszeti Gyar Nyrt +1.56%

Company Profile

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others. Its subsidiaries include Mayne Pharma International Pty Ltd, Mayne Holdings US Inc, Mayne Pharma LLC, and others.